Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Array Genotyping System

By Drug Discovery Trends Editor | November 5, 2008

Applied Biosystems Inc. has commercialized an analysis system to enable researchers to perform high-sample-throughput genotyping studies.  The TaqMan OpenArray genotyping system provides life scientists with Applied Biosystems’ TaqMan SNP genotyping assays and TaqMan DME assays in a flexible format.

Researchers using this integrated platform can experience an end-to-end genotyping workflow of less than eight hours. Single nucleotide polymorphism (SNP) genotyping studies can also be performed on this platform. The TaqMan OpenArray genotyping system will provide researchers and commercial organization with a validation and screening tool that has the potential to improve genotyping efficiencies and simplify their workflows, according to the company.

The TaqMan OpenArray genotyping system enables researchers to perform studies that investigate SNPs across thousands to tens of thousands of samples.

The TaqMan OpenArray genotyping plates provide researchers with the flexibility to deploy assays in many different configurations. Each TaqMan OpenArray genotyping plate contains 3,072 through-holes arranged in 48 sub-arrays of 64 through-holes each.

The system includes an instrument platform, reagents, and consumables, with the main components consisting of the TaqMan OpenArray genotyping instrument platform and TaqMan OpenArray genotyping plates that are pre-loaded with pre-designed or custom TaqMan SNP genotyping or drug metabolizing enzyme (DME) assays.

Applied Biosystems 


Filed Under: Drug Discovery

 

Related Articles Read More >

Korean team reports all-in-one cancer nanomedicine in pre-clinical studies
Nektar’s Phase 2b atopic dermatitis win triggers 1,746% analyst target surge, but legal tussle with ex-partner Lilly could complicate path forward
Dupixent approved to treat bullous pemphigoid
EVEREST lead investigator on why Dupixent sets a new bar for treating coexisting CRSwNP and asthma
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE